bioAffinity Technologies, Inc. has made a significant advancement in its efforts to combat lung cancer. On October 8, 2026, the company announced that the Japan Patent Office issued a Notice of Allowance for its CyPath® Lung test, a method designed to predict the likelihood of lung cancer at early stages. This development is crucial as it positions bioAffinity to enhance its diagnostic capabilities in a competitive market.
Receiving a patent is a critical milestone for bioAffinity Technologies, as it not only protects its intellectual property but also strengthens its market position in the healthcare sector. The CyPath® Lung test is aimed at improving early detection of lung cancer, which is vital for increasing survival rates. This patent could potentially lead to increased partnerships and collaborations, as well as drive revenue growth for the company.
Background
bioAffinity Technologies, Inc., incorporated in Delaware, operates in the commercial physical and biological research sector (SIC 8731). The company trades on the Nasdaq under the ticker symbols BIAF and BIAFW. Its focus on innovative diagnostic solutions positions it uniquely within the healthcare landscape, particularly in the field of cancer detection.
What the Filing Says
The recent filing indicates that bioAffinity Technologies has received a Notice of Allowance from the Japan Patent Office, signifying the office's intention to grant a patent for the CyPath® Lung test. The filing states, "On October 8, 2026, bioAffinity Technologies, Inc. issued a press release announcing that the Japan Patent Office has issued a Notice of Allowance, indicating its intention to grant a patent to the Company for the method of predicting the likelihood of lung cancer powered by the CyPath® Lung test for early-stage lung cancer." This announcement is a pivotal moment for the company as it seeks to expand its market share in cancer diagnostics.
Impact
This patent approval may significantly impact various stakeholders, including healthcare providers, patients, and investors. For healthcare providers, the availability of a patented diagnostic tool could enhance their ability to detect lung cancer early, potentially leading to better patient outcomes. Patients may benefit from improved diagnostic options, while investors could see increased confidence in the company's future growth prospects.
What's Next
The filing does not specify what happens next regarding the commercialization of the CyPath® Lung test or any further developments related to the patent process. However, the company may pursue additional regulatory approvals and partnerships to bring this innovative diagnostic tool to market.